Lexicon to Showcase Diabetes and Pain Drug Data at ADA 2026
Event summary
- Lexicon will present data on sotagliflozin for Type 1 diabetes and pilavapadin for diabetic neuropathic pain at ADA 2026 Scientific Sessions (June 5-8).
- Sotagliflozin NDA resubmission for Type 1 diabetes on track for mid-2026.
- Pilavapadin Phase 1 data shows renal function does not affect pharmacokinetics.
- Presentations include pooled analysis of sotagliflozin efficacy and Phase 1 pharmacokinetics of pilavapadin.
The big picture
Lexicon's presentations at ADA 2026 highlight its focus on expanding into diabetes and pain markets. The company's dual approach of targeting both Type 1 diabetes and diabetic neuropathic pain positions it in high-growth therapeutic areas. Success in these indications could significantly boost its pipeline value, particularly if sotagliflozin gains regulatory approval.
What we're watching
- Regulatory Timing
- Whether Lexicon can meet its mid-2026 target for sotagliflozin NDA resubmission.
- Clinical Efficacy
- How sotagliflozin's glycemic improvement data across subgroups impacts its market potential.
- Pain Drug Development
- The pace at which pilavapadin advances through clinical trials given its novel mechanism.